ArticleJournal of neuro-oncology2005
Molecular biology of medulloblastoma: will it ever make a difference to clinical management?
Article in Journal of neuro-oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.Pediatric blood & cancer · 2008Trial
- MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons.International journal of molecular sciences · 2014Review
- Analysis of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2011Article
- Lack of prognostic significance of survivin in pediatric medulloblastoma.Pathology oncology research : POR · 2011Article
- Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop.Neuro-oncology · 2011Review
- Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Article
- Review
- Chemotherapy for malignant brain tumors of childhood.Journal of child neurology · 2008Review
- Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8.BMC cancer · 2006Article
- Medulloblastoma: therapy and biologic considerations.Current neurology and neuroscience reports · 2006Review
- Heparanase expression and TrkC/p75NTR ratios in human medulloblastoma.Clinical & experimental metastasis · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over the last 10 years approximately 750 children with medulloblastoma have been treated on consortia based clinical trials at an estimated cost of over 150 million US dollars. Despite this enormous effort, no meaningful molecular data has been generated that will inform the next generation of clinical studies. It is imperative that the neuro-oncology community give greater priority to studies of medulloblastoma molecular biology: unless we do this our patients will face a bleak future in which there is no accurate disease-risk stratification tool and no effective new treatments. We review some of the reasons we have failed to translate knowledge of medulloblastoma disease biology to the clinic and look forward to the next generation of clinical and molecular studies that are seeking to correct this.
Indexed as
Identifiers
16195803What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.